BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van de Ven N, Fortunak J, Simmons B, Ford N, Cooke GS, Khoo S, Hill A. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology. 2015;61:1174-1182. [PMID: 25482139 DOI: 10.1002/hep.27641] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
2 Cohn J, Roberts T, Amorosa V, Lemoine M, Hill A. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment. Curr Opin HIV AIDS 2015;10:369-73. [PMID: 26185920 DOI: 10.1097/COH.0000000000000180] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
3 Kumar S, Jacobson IM. The extinction of chronic viral hepatitis? Clin Liver Dis (Hoboken) 2015;6:75-7. [PMID: 31040993 DOI: 10.1002/cld.502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Liu CH, Sun HY, Liu CJ, Sheng WH, Hsieh SM, Lo YC, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. Aliment Pharmacol Ther 2018;47:1690-8. [PMID: 29665069 DOI: 10.1111/apt.14647] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
5 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
6 Vella S, Wilson D. Access to medicines: lessons from the HIV response. Lancet HIV 2017;4:e147-9. [PMID: 28359443 DOI: 10.1016/S2352-3018(17)30052-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Singh P, Dass JF. A multifaceted computational report on the variants effect on KIR2DL3 and IFNL3 candidate gene in HCV clearance. Mol Biol Rep 2016;43:1101-17. [PMID: 27461217 DOI: 10.1007/s11033-016-4044-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
9 Tsay SC, Lin SY, Huang WC, Hsu MH, Hwang KC, Lin CC, Horng JC, Chen IC, Hwu JR, Shieh FK, Leyssen P, Neyts J. Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus. Molecules 2016;21:E228. [PMID: 26901180 DOI: 10.3390/molecules21020228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
10 Heath K. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C. Clinicoecon Outcomes Res 2018;10:539-50. [PMID: 30288069 DOI: 10.2147/CEOR.S171248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Boyer S, Baudoin M, Nishimwe ML, Santos M, Lemoine M, Maradan G, Sylla B, Kouanfack C, Carrieri P, Mourad A, Rouveau N, Moh R, Seydi M, Attia A, Woode ME, Lacombe K. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa. BMC Health Serv Res 2022;22. [DOI: 10.1186/s12913-021-07289-0] [Reference Citation Analysis]
13 Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-184. [PMID: 30647010 DOI: 10.1016/s2468-1253(18)30270-x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 79] [Article Influence: 90.0] [Reference Citation Analysis]
14 Spaulding AC, Chhatwal J, Adee MG, Lawrence RT, Beckwith CG, von Oehsen W. Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism. J Correct Health Care 2019;25:15-24. [PMID: 30322323 DOI: 10.1177/1078345818805770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. Journal of Virus Eradication 2017;3:117-23. [DOI: 10.1016/s2055-6640(20)30329-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 1] [Article Influence: 17.2] [Reference Citation Analysis]
16 Edlin BR. Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infect Dis 2016;16:e196-201. [PMID: 27421993 DOI: 10.1016/S1473-3099(16)30005-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
17 Ferenci P, Caruntu FA, Lengyel G, Messinger D, Bakalos G, Flisiak R. Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. Infect Dis Ther. 2016;5:113-124. [PMID: 27228998 DOI: 10.1007/s40121-016-0110-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Suthar AB, Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med. 2015;12:e1001795. [PMID: 25757228 DOI: 10.1371/journal.pmed.1001795] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
19 Lombardi A, Mondelli MU; ESCMID Study Group for Viral Hepatitis (ESGVH). Hepatitis C: Is eradication possible? Liver Int 2019;39:416-26. [DOI: 10.1111/liv.14011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
20 Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015; 7(5): 725-737 [PMID: 25914773 DOI: 10.4254/wjh.v7.i5.725] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
21 Guo J, Wang J, Zhang J, Fortunak J, Hill A. Current prices versus minimum costs of production for CFTR modulators. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.04.007] [Reference Citation Analysis]
22 Gray AL, Wirtz VJ, 't Hoen EF, Reich MR, Hogerzeil HV. Essential medicines are still essential. Lancet 2015;386:1601-3. [PMID: 26595616 DOI: 10.1016/S0140-6736(15)00514-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
23 Hill A, Simmons B, Gotham D, Fortunak J. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. Journal of Virus Eradication 2016;2:28-40. [DOI: 10.1016/s2055-6640(20)30691-9] [Cited by in Crossref: 41] [Article Influence: 6.8] [Reference Citation Analysis]
24 Vernaz N, Girardin F, Goossens N, Brügger U, Riguzzi M, Perrier A, Negro F. Drug Pricing Evolution in Hepatitis C. PLoS One 2016;11:e0157098. [PMID: 27310294 DOI: 10.1371/journal.pone.0157098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
25 Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.01.009] [Reference Citation Analysis]
26 Liu CH, Huang YJ, Yang SS, Chang CH, Yang SS, Sun HY, Liu CJ, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep 2018;8:13699. [PMID: 30209349 DOI: 10.1038/s41598-018-32060-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
27 Cooke GS. Scaling-up HCV treatment to achieve WHO targets by 2030. Trop Med Int Health 2017;22:372-4. [DOI: 10.1111/tmi.12837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Enomoto H, Sakai Y, Iwata Y, Takata R, Aizawa N, Ikeda N, Hasegawa K, Nakano C, Nishimura T, Yoh K, Ishii A, Takashima T, Nishikawa H, Iijima H, Nishiguchi S. Development of risky varices in alcoholic cirrhosis with a well-maintained nutritional status. World J Hepatol 2015; 7(21): 2358-2362 [PMID: 26413226 DOI: 10.4254/wjh.v7.i21.2358] [Reference Citation Analysis]
29 Feld JJ, Foster GR. Second generation direct-acting antivirals – Do we expect major improvements? Journal of Hepatology 2016;65:S130-42. [DOI: 10.1016/j.jhep.2016.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
30 Spaulding AC, Adee MG, Lawrence RT, Chhatwal J, von Oehsen W. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination. Infect Dis Clin North Am 2018;32:323-45. [PMID: 29778259 DOI: 10.1016/j.idc.2018.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
31 Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. Hepatology 2016;64:1331-42. [PMID: 26926906 DOI: 10.1002/hep.28527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
32 Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212 [PMID: 29527256 DOI: 10.4254/wjh.v10.i2.186] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
33 Zhu J, Hazen RJ, Joyce C, Delpino A, Kirkham HS, Strickland CD, Markes-wilson S, Kim T, Kang M, Rubin RA, Stein LL. Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals. Journal of the American Pharmacists Association 2018;58:89-93.e2. [DOI: 10.1016/j.japh.2017.10.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
34 Niessen LW, Khan JAM. Universal access to medicines. The Lancet 2016;387:9-11. [DOI: 10.1016/s0140-6736(15)00552-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
35 Wiesmann F, Braun P. Significance of HCV RNA monitoring in the era of new potent therapies. Expert Rev Anti Infect Ther 2016;14:837-44. [PMID: 27424603 DOI: 10.1080/14787210.2016.1214355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
36 Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE 3rd, Hill A. Estimated generic prices for novel treatments for drug-resistant tuberculosis. J Antimicrob Chemother 2017;72:1243-52. [PMID: 28073970 DOI: 10.1093/jac/dkw522] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]